• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • Importing Drugs and Medical Devices for Urgent Clinical Use in GBA

Importing Drugs and Medical Devices for Urgent Clinical Use in GBA

Friday, 25 March 2022 / Published in Medical Device, Medical Devices Listing in Hong Kong, News, NMPA Registration in China

Importing Drugs and Medical Devices for Urgent Clinical Use in GBA

Importing drugs and medical devices to the GBA via Hong Kong and Macao attracted foreign manufacturers, medtech and pharmaceutical companies to consider since the expedited pathway have been implemented step-by-step in recent years. According to the Interim Provisions on the Administration of Imported Medicines and Medical Devices for Urgent Clinical Use in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) in August 2021, five GBA hospitals have been designated to use drugs and medical devices from Hong Kong upon the approval of the Guangdong MPA:

  • HKU-SZH
  • Modern Hospital Guangzhou
  • Guangzhou United Family Hospital
  • C-MER (Zhuhai) Dennis Lam Eye Hospital
  • Zhongshan Chenxinghai Hospital

On February 18, 2022, the Guangdong MPA announced a list of the second batch of imported Hong Kong- and Macao-registered drugs and medical devices for urgent clinical use in the Greater Bay Area covering 6 drugs and 1 medical device:

  • Alpelisib Film-coated Tablets (drug)
  • Erdafitinib tablets (drug)
  • Budesonide Prolonged Release Capsules (drug)
  • Hydroxocobalamin Powder For Solution For Infusion (drug)
  • Brolucizumab (drug)
  • Capmatinib (drug)
  • CliniMACS Plus System (medical device)

On March 14, 2022, the Guangdong MPA (Medical Products Administration) announced a new version of approval document format will be used by the authorities from March 1, 2022, onwards. A total of 15 drugs and 5 medical devices have been approved so far for import into the GBA including the following drug and medical device approved in March 2022:

  • Lorlatinib (drug)
  • Brilliant blue G dye for eye surgery (medical device)

Cisema is competent in supporting regulatory affairs for drugs and medical devices in Hong Kong and China. Contact Cisema if you would like to learn more.

Tagged under: GBA, Greater Bay Area

What you can read next

China urgently needed drugs temporary import workflow
China “urgently needed drugs” temporary import workflow has been issued
China's digital health regulatory framework
China’s digital health regulatory framework for SaMD – Cisema article featured on RAPS Weekly
On-site Inspection Measures for Special Food Products in China

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • China medical device sampling inspection results

    China medical device sampling inspection results no.4 of 2022

    China medical device sampling inspection result...
  • NMPA cosmetic sampling inspection

    The NMPA Cosmetic Sampling Inspection measures come into force on March 1, 2023

    NMPA Cosmetic Sampling Inspection Measures come...
  • China cosmetics quality safety responsibilities

    China cosmetics quality and safety responsibilities regulations released

    China cosmetics quality and safety responsibili...
  • China cosmetics efficacy claims FAQ

    China cosmetics efficacy claims FAQ available to answer key questions

    China cosmetics efficacy claims FAQ is availabl...
  • China cosmetics GMP inspections

    China cosmetics GMP inspections points have been finalised

    China cosmetics GMP inspections points and judg...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP
Cookies on Cisema
Learn more about Cisema's Privacy Policy.